<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="case-report"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cureus</journal-id><journal-id journal-id-type="iso-abbrev">Cureus</journal-id><journal-id journal-id-type="issn">2168-8184</journal-id><journal-title-group><journal-title>Cureus</journal-title></journal-title-group><issn pub-type="epub">2168-8184</issn><publisher><publisher-name>Cureus</publisher-name><publisher-loc>Palo Alto (CA)</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40400877</article-id><article-id pub-id-type="pmc">PMC12094802</article-id><article-id pub-id-type="doi">10.7759/cureus.82709</article-id><article-categories><subj-group subj-group-type="heading"><subject>Ophthalmology</subject></subj-group></article-categories><title-group><article-title>Successful Response to Intravitreal Faricimab Injections in a Case of Neovascular Age-Related Macular Degeneration in Vitrectomized Eyes</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Muacevic</surname><given-names>Alexander</given-names></name></contrib><contrib contrib-type="editor"><name><surname>Adler</surname><given-names>John R</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Chujo</surname><given-names>Shinichiro</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Matsubara</surname><given-names>Hisashi</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Mase</surname><given-names>Yoko</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Kato</surname><given-names>Kumiko</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Kondo</surname><given-names>Mineo</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib></contrib-group><aff id="aff-1">
<label>1</label>
Department of Ophthalmology, Mie University Graduate School of Medicine, Tsu, JPN </aff><author-notes><corresp id="cor1">
Shinichiro Chujo <email>shinchujo21@gmail.com</email>
</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>21</day><month>4</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>4</month><year>2025</year></pub-date><volume>17</volume><issue>4</issue><elocation-id>e82709</elocation-id><history><date date-type="accepted"><day>21</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025, Chujo et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Chujo et al.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xlink:href="https://www.cureus.com/articles/353238-successful-response-to-intravitreal-faricimab-injections-in-a-case-of-neovascular-age-related-macular-degeneration-in-vitrectomized-eyes">This article is available from https://www.cureus.com/articles/353238-successful-response-to-intravitreal-faricimab-injections-in-a-case-of-neovascular-age-related-macular-degeneration-in-vitrectomized-eyes</self-uri><abstract><p>The half-life of anti-vascular endothelial growth factor (anti-VEGF) drugs shortens significantly after vitrectomy due to an increased intraocular pharmacokinetic clearance caused by the absence of the vitreous gel. This reduced half-life can limit the therapeutic effect of these intravitreal agents and complicate the management of conditions such as neovascular age-related macular degeneration (nAMD). We report a case of nAMD in a vitrectomized eye that showed inadequate response to both aflibercept and brolucizumab, but experienced effective suppression of exudation following intravitreal administration of faricimab. This case suggests that faricimab may offer a therapeutic benefit in managing exudative changes in vitrectomized eyes with nAMD.</p></abstract><kwd-group kwd-group-type="author"><kwd>avitreous</kwd><kwd>faricimab</kwd><kwd>intravitreal injection</kwd><kwd>neovasucular age related macular degeneration</kwd><kwd>oct (optical coherence tomography)</kwd><kwd>vitrectomy</kwd><kwd>&#x000a0;retina</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>The incidence of neovascular age-related macular degeneration (nAMD) is increasing worldwide&#x000a0;[<xref rid="REF1" ref-type="bibr">1</xref>].&#x000a0;The first-line treatment for nAMD typically involves intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents [<xref rid="REF2" ref-type="bibr">2</xref>], administered following a Treat-and-Extend (TAE) regimen [<xref rid="REF3" ref-type="bibr">3</xref>]. Although the TAE regimen has been reported to maintain long-term visual acuity, the treatment often needs to be continued over an extended period&#x000a0;[<xref rid="REF4" ref-type="bibr">4</xref>].&#x000a0;As long-term repeated injections can burden patients, treatment discontinuation has been proposed in some cases [<xref rid="REF5" ref-type="bibr">5</xref>].</p><p>However, our group reported that approximately 50% of the cases had a recurrence within one year, and approximately 73.9% had a recurrence within five years after discontinuation of the anti-VEGF intravitreal injections. This led to the understanding that long-term anti-VEGF therapy is essential to prevent the recurrence of neovascularization [<xref rid="REF6" ref-type="bibr">6</xref>].</p><p>Following vitrectomy, the replacement of the vitreous gel with aqueous humor leads to an accelerated intraocular drug clearance, thereby shortening the intravitreal half-life of anti-VEGF agents [<xref rid="REF7" ref-type="bibr">7</xref>,<xref rid="REF8" ref-type="bibr">8</xref>]. This can decrease their long-term effectiveness&#x000a0;and&#x000a0;make the treatment of nAMD&#x000a0;and other conditions transient.</p><p>We report a case of nAMD in an eye that had undergone vitrectomy with the replacement of the vitreous gel. It&#x000a0;did not respond to treatment with either aflibercept or brolucizumab. However, there was a good suppression of exudation after intravitreal injections of&#x000a0;faricimab. Significantly, the exudation remained suppressed even for a long time after treatment discontinuation.</p></sec><sec sec-type="cases"><title>Case presentation</title><p>This case is of an 82-year-old male patient. He was referred to our hospital from a private clinic for the treatment of a displaced intraocular lens (IOL) in his right eye.</p><p>He&#x000a0;had previously been diagnosed with nAMD in the right eye and had been receiving fixed doses of aflibercept for eight weeks, with good fluid control. The best-corrected visual acuity (BCVA) was 20/25 and intraocular pressure was 13 mmHg in the right eye. Slit lamp examination revealed IOL deviation in the same&#x000a0;eye. Optical coherence tomography&#x000a0;(OCT) showed that it had no exudative changes and a dry macula was maintained (Figures <xref rid="FIG1" ref-type="fig">1A</xref>, <xref rid="FIG1" ref-type="fig">1B</xref>)</p><fig position="anchor" fig-type="figure" id="FIG1"><label>Figure 1</label><caption><title> Slit-lamp and optical coherence tomographic (OCT) images of the patient's right eye with neovascular age-related macular degeneration (nAMD)</title><p>A: IOL dislocation is observed.
B: At the time of the initial examination, the macula was dry.
IOL, intraocular lens</p></caption><graphic xlink:href="cureus-0017-00000082709-i01" position="float"/></fig><p>The patient underwent vitreous surgery and IOL scleral fixation. The postoperative course was good, but the exudative changes recurred about four weeks after the surgery&#x000a0;(Figure <xref rid="FIG2" ref-type="fig">2A</xref>). Therefore, we started intravitreal injections with aflibercept (IVA) again, but the subretinal fluid (SRF) recurred within eight weeks&#x000a0;(Figures <xref rid="FIG2" ref-type="fig">2B</xref>, <xref rid="FIG2" ref-type="fig">2C</xref>)</p><fig position="anchor" fig-type="figure" id="FIG2"><label>Figure 2</label><caption><title>OCT image during the follow-up period after vitrectomy</title><p>A: OCT findings four weeks after the surgery; SRF observed.
B: OCT findings four weeks after the first administration of aflibercept; SRF persists.
C: OCT findings four weeks after the second administration of aflibercept; SRF persists.
OCT, Optical coherence tomography; SRF, subretinal fluid</p></caption><graphic xlink:href="cureus-0017-00000082709-i02" position="float"/></fig><p>The patient reported no subjective change in symptoms during this period. We then switched to ranibizumab, considering the possibility of tachyphylaxis to aflibercept, but there was no improvement in SRF at four weeks after the injection&#x000a0;(Figures <xref rid="FIG3" ref-type="fig">3A</xref>-<xref rid="FIG3" ref-type="fig">3C</xref>).</p><fig position="anchor" fig-type="figure" id="FIG3"><label>Figure 3</label><caption><title>OCT results after switching to ranibizumab</title><p>A: OCT image before ranibizumab administration; SRF present.
B: OCT image four weeks after ranibizumab administration; SRF persists.
C: OCT image four weeks after switching back to aflibercept; SRF persists.
OCT, optical coherence tomography;&#x000a0;SRF, subretinal fluid</p></caption><graphic xlink:href="cureus-0017-00000082709-i03" position="float"/></fig><p>The possibility of tachyphylaxis to aflibercept as a cause of the poor response was ruled out.&#x000a0;We then switched to brolucizumab, but there was no improvement in SRF at four weeks after the injection&#x000a0;(Figures <xref rid="FIG4" ref-type="fig">4A</xref>, <xref rid="FIG4" ref-type="fig">4B</xref>).</p><fig position="anchor" fig-type="figure" id="FIG4"><label>Figure 4</label><caption><title>OCT results after switching to brolucizumab</title><p>A: OCT image before brolucizumab administration; SRF observed.
B: OCT four weeks after brolucizumab administration; SRF persists.
OCT,&#x000a0;optical coherence tomography; SRF, subretinal fluid
&#x000a0;</p></caption><graphic xlink:href="cureus-0017-00000082709-i04" position="float"/></fig><p>As brolucizumab was also ineffective, photodynamic therapy was considered as a treatment option. However, after discussion with the patient, it was decided to proceed with faricimab administration. Hence, we switched to faricimab, with another loading therapy (Figure <xref rid="FIG5" ref-type="fig">5A</xref>). After the first intravitreal injection of faricimab, a slight improvement in SRF was observed&#x000a0;(Figure <xref rid="FIG5" ref-type="fig">5B</xref>). By the&#x000a0;second intravitreal injection, SRF had disappeared&#x000a0;(Figure <xref rid="FIG5" ref-type="fig">5C</xref>). And after the loading therapy was over, the patient's macula became dry&#x000a0;(Figure <xref rid="FIG5" ref-type="fig">5D</xref>).</p><fig position="anchor" fig-type="figure" id="FIG5"><label>Figure 5</label><caption><title>OCT findings after switching to faricimab</title><p>A: OCT before administration
B: OCT four weeks after the first administration of faricimab; a decrease in SRF&#x000a0;observed.
C: OCT four weeks after the second administration of faricimab;&#x000a0;disappearance of SRF observed.
D. OCT four weeks after the third administration of faricimab; SRF remains absent.
OCT, optical coherence tomography;&#x000a0;SRF, subretinal fluid</p></caption><graphic xlink:href="cureus-0017-00000082709-i05" position="float"/></fig><p>The patient was scheduled to receive maintenance therapy, but then liver cancer was detected, and he stopped attending the hospital for about eight months while undergoing chemotherapy. However, the dry macula was maintained (Figures <xref rid="FIG6" ref-type="fig">6A</xref>, <xref rid="FIG6" ref-type="fig">6B</xref>).</p><fig position="anchor" fig-type="figure" id="FIG6"><label>Figure 6</label><caption><title>OCT after discontinuation of treatment</title><p>A: OCT image before discontinuation of treatment. The dry macula is maintained.
B: OCT image at the first visit after discontinuation of treatment. The dry macula is maintained.
C: OCT image&#x000a0;one year&#x000a0;after discontinuation.
OCT, optical coherence tomography</p></caption><graphic xlink:href="cureus-0017-00000082709-i06" position="float"/></fig><p>At this stage, we had a thorough discussion with the patient about whether to follow a fixed dosing regimen or to adopt a pro re nata (PRN) approach based on the disease progression. The patient wished to continue with the latter, so we continued to monitor his condition. As of now, a year has passed since the last injection. The&#x000a0;dry macula was maintained&#x000a0;(Figure <xref rid="FIG6" ref-type="fig">6C</xref>)&#x000a0;and the BCVA was 20/60 in the right eye.</p><p>A summary of the treatment course and the therapeutic responses is presented in Table <xref rid="TAB1" ref-type="table">1</xref> to facilitate understanding of the patient's clinical course.</p><table-wrap position="float" id="TAB1"><label>Table 1</label><caption><title>Summary of the therapeutic agents used and the treatment course</title><p>SRF, subretinal fluid</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Timeline</td><td rowspan="1" colspan="1">Drug</td><td rowspan="1" colspan="1">Interval</td><td rowspan="1" colspan="1">OCT Findings</td><td rowspan="1" colspan="1">Response</td></tr><tr><td rowspan="1" colspan="1">Pre-vitrectomy</td><td rowspan="1" colspan="1">Aflibercept</td><td rowspan="1" colspan="1">Fixed dose 8 weeks</td><td rowspan="1" colspan="1">Dry macula</td><td rowspan="1" colspan="1">Good response</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">4 weeks post-op</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">SRF recurrence</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">Restart Injection</td><td rowspan="1" colspan="1">Aflibercept</td><td rowspan="1" colspan="1">Once</td><td rowspan="1" colspan="1">SRF persists at 4 &#x00026; 8 weeks</td><td rowspan="1" colspan="1">No response</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Switch #1</td><td rowspan="1" colspan="1">Ranibizumab</td><td rowspan="1" colspan="1">Once</td><td rowspan="1" colspan="1">SRF remains at 4 weeks</td><td rowspan="1" colspan="1">No response</td></tr><tr><td rowspan="1" colspan="1">Switch #2</td><td rowspan="1" colspan="1">Aflibercept</td><td rowspan="1" colspan="1">Once</td><td rowspan="1" colspan="1">SRF remains at 4 weeks</td><td rowspan="1" colspan="1">No response</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Switch #3</td><td rowspan="1" colspan="1">Brolucizumab</td><td rowspan="1" colspan="1">Once</td><td rowspan="1" colspan="1">SRF remains at 4 weeks</td><td rowspan="1" colspan="1">No response</td></tr><tr><td rowspan="1" colspan="1">Switch #456 (Loading)</td><td rowspan="1" colspan="1">Faricimab</td><td rowspan="1" colspan="1">Once a month for 3 months</td><td rowspan="1" colspan="1">SRF reduction, dry macula after the second dose</td><td rowspan="1" colspan="1">Good response</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">8 months follow-up</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">Dry macula maintained</td><td rowspan="1" colspan="1">Maintained</td></tr><tr><td rowspan="1" colspan="1">12 months follow-up</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">Dry macula maintained</td><td rowspan="1" colspan="1">Maintained</td></tr></tbody></table></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p>We have presented our findings in one case of nAMD in which the exudative activity was not controlled by brolucizumab and only by&#x000a0;intravitreal injections of faricimab. Interestingly,&#x000a0;the disease activity was controlled for at least a&#x000a0;year.&#x000a0;In general, reports suggest that when anti-VEGF drugs are suspended, the disease recurs within a year in more than 50% of the cases [<xref rid="REF9" ref-type="bibr">9</xref>]. In our case, no recurrence was observed for approximately one year after the intravitreal injection of&#x000a0;faricimab was stopped.</p><p>Intravitreal injections of brolucizumab failed to achieve adequate fluid control, whereas initiating loading therapy with faricimab resulted in good fluid resolution. This improvement is likely due to faricimab&#x02019;s enhanced ability to suppress nAMD activity. The underlying reason may be linked to the altered clearance of anti-VEGF agents in eyes lacking the vitreous gel. A report by Lee et al. has shown that the effect of anti-VEGF drugs is reduced in an eye with a vitreous replacement after vitrectomy,&#x000a0;likely due to accelerated drug clearance in the saline-filled cavity [<xref rid="REF10" ref-type="bibr">10</xref>].</p><p>It has also been reported that the pharmacokinetic half-life of anti-VEGF drugs varies&#x000a0;indirectly&#x000a0;with the molecular weight of the drug&#x000a0;[<xref rid="REF10" ref-type="bibr">10</xref>]. In non-vitrectomized eyes, the molecular weights of aflibercept, brolucizumab, and ranibizumab are approximately 115 kDa, 26 kDa, and 48 kDa, respectively [<xref rid="REF11" ref-type="bibr">11</xref>-<xref rid="REF13" ref-type="bibr">13</xref>]. Faricimab (149 kDa) may benefit from its relatively large molecular size, potentially reducing clearance in vitrectomized eyes&#x000a0;[<xref rid="REF14" ref-type="bibr">14</xref>]. Thus, we can consider the possibility that faricimab, with its large molecular weight, was effective in an eye where the vitreous gel was replaced by saline, leading to&#x000a0;decreased&#x000a0;clearance.</p><p>We also considered the possibility that the long-term suppression of disease activity observed with faricimab loading therapy may have been influenced by prior disease control achieved through the fixed eight-week aflibercept administration before surgery. Kataoka et al. reported that switching to faricimab was effective in patients with nAMD who were unable to extend the dosing interval with aflibercept, showing positive outcomes six months after the switch [<xref rid="REF15" ref-type="bibr">15</xref>]. Similarly, Machida et al. demonstrated that faricimab was particularly effective in cases characterized by a thin choroid, non-polypoidal choroidal vasculopathy (non-PCV), and a short dosing interval prior to switching [<xref rid="REF16" ref-type="bibr">16</xref>]. In addition to its higher molecular weight, faricimab&#x02019;s dual inhibition of VEGF-A and Angiopoietin-2 may have contributed to sustained disease control by enhancing vascular stability and reducing inflammation, which could be especially beneficial in&#x000a0;vitrectomized eyes&#x000a0;[<xref rid="REF14" ref-type="bibr">14</xref>].</p><p>As indicated by these reports,&#x000a0;there are cases of nAMD in which a switch to faricimab is effective. This patient also showed the presence of a thin choroid. At the initial visit, the subfoveal choroidal thickness was 181 &#x003bc;m, which is thinner than that observed in the general population (283.7&#x000b1;84.1 &#x003bc;m) [<xref rid="REF17" ref-type="bibr">17</xref>]. We hence consider the possibility that a switch to faricimab was effective.</p><p>The findings of this case report are limited by its single-patient design.&#x000a0;Additional studies with larger sample sizes are needed to further explore and substantiate the outcomes observed.</p><p>Our findings indicate that faricimab may be effective in cases of nAMD in vitrectomized eyes. However, further studies with a larger patient population are needed to validate these results.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>We reported a case of nAMD in a vitrectomized eye where exudative changes were successfully suppressed over the long term following a switch to faricimab. The patient had shown poor response to previous treatments with aflibercept and brolucizumab, but faricimab led to resolution of subretinal fluid and stabilization of the retinal morphology.</p><p>This case suggests that faricimab, a dual inhibitor of VEGF-A and Angiopoietin-2 with a relatively large molecular weight, may be particularly effective in eyes that have undergone vitrectomy, where intravitreal drug clearance is accelerated. Although limited by being a single case report, the present findings support the need for further investigation into the pharmacologic advantages of faricimab in vitrectomized eyes with treatment-resistant nAMD.
&#x000a0;</p></sec></body><back><ack><p>The authors thank Professor Emeritus Duco Hamasaki of the Bascom Palmer Eye Institute of the University of Miami for critical discussion and final manuscript revisions.</p></ack><fn-group content-type="conflict"><title>Disclosures</title><fn fn-type="COI-statement"><p><bold>Human subjects:</bold> Consent for treatment and open access publication was obtained or waived by all participants in this study. Ethics Committee of Mie University Hospital issued approval H2021-088, UMIN000044144.</p><p><bold>Conflicts of interest:</bold> In compliance with the ICMJE uniform disclosure form, all authors declare the following:</p><p><bold>Payment/services info:</bold> All authors have declared that no financial support was received from any organization for the submitted work.</p><p><bold>Financial relationships:</bold> All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.</p><p><bold>Other relationships:</bold> All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</p></fn></fn-group><fn-group content-type="other"><title>Author Contributions</title><fn fn-type="other"><p><bold>Concept and design:</bold>&#x000a0; Shinichiro Chujo, Yoko Mase, Kumiko Kato, Mineo Kondo</p><p><bold>Acquisition, analysis, or interpretation of data:</bold>&#x000a0; Shinichiro Chujo, Hisashi Matsubara</p><p><bold>Drafting of the manuscript:</bold>&#x000a0; Shinichiro Chujo</p><p><bold>Critical review of the manuscript for important intellectual content:</bold>&#x000a0; Shinichiro Chujo, Hisashi Matsubara, Yoko Mase, Kumiko Kato, Mineo Kondo</p><p><bold>Supervision:</bold>&#x000a0; Mineo Kondo</p></fn></fn-group><ref-list><title>References</title><ref id="REF1"><label>1</label><element-citation publication-type="journal"><article-title>Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis</article-title><source>Lancet Glob Health</source><person-group>
<name><surname>Wong</surname><given-names>WL</given-names></name>
<name><surname>Su</surname><given-names>X</given-names></name>
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Cheung</surname><given-names>CM</given-names></name>
<name><surname>Klein</surname><given-names>R</given-names></name>
<name><surname>Cheng</surname><given-names>CY</given-names></name>
<name><surname>Wong</surname><given-names>TY</given-names></name>
</person-group><fpage>0</fpage><lpage>16</lpage><volume>2</volume><year>2014</year><uri xlink:href="https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(13)70145-1/fulltext">https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(13)70145-1/fulltext</uri></element-citation></ref><ref id="REF2"><label>2</label><element-citation publication-type="journal"><article-title>Ranibizumab for neovascular age-related macular degeneration</article-title><source>N Engl J Med</source><person-group>
<name><surname>Rosenfeld</surname><given-names>PJ</given-names></name>
<name><surname>Brown</surname><given-names>DM</given-names></name>
<name><surname>Heier</surname><given-names>JS</given-names></name>
<name><surname>Boyer</surname><given-names>DS</given-names></name>
<name><surname>Kaiser</surname><given-names>PK</given-names></name>
<name><surname>Chung</surname><given-names>CY</given-names></name>
<name><surname>Kim</surname><given-names>RY</given-names></name>
</person-group><fpage>1419</fpage><lpage>1431</lpage><volume>355</volume><year>2006</year><pub-id pub-id-type="pmid">17021318</pub-id>
</element-citation></ref><ref id="REF3"><label>3</label><element-citation publication-type="journal"><article-title>Randomized trial of treat- and-extend versus monthly dosing for neovascular age- related macular degeneration: 2-year results of the TREX-AMD study</article-title><source>Ophthalmol Retina</source><person-group>
<name><surname>Wykoff</surname><given-names>CC</given-names></name>
<name><surname>Ou</surname><given-names>WC</given-names></name>
<name><surname>Brown</surname><given-names>DM</given-names></name>
<etal/>
</person-group><fpage>314</fpage><lpage>321</lpage><volume>1</volume><year>2017</year><pub-id pub-id-type="pmid">31047517</pub-id>
</element-citation></ref><ref id="REF4"><label>4</label><element-citation publication-type="journal"><article-title>Cross-sectional study evaluating burden and depressive symptoms in family carers of persons with age-related macular degeneration in Australia</article-title><source>BMJ Open</source><person-group>
<name><surname>Jin</surname><given-names>I</given-names></name>
<name><surname>Tang</surname><given-names>D</given-names></name>
<name><surname>Gengaroli</surname><given-names>J</given-names></name>
<etal/>
</person-group><fpage>0</fpage><volume>11</volume><year>2021</year></element-citation></ref><ref id="REF5"><label>5</label><element-citation publication-type="journal"><article-title>Treat-and-Extend Regimens for the Management of Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy: Consensus and Recommendations From the Asia-Pacific Vitreo-retina Society</article-title><source>2021</source><fpage>10</fpage><volume>507-18</volume><year>10</year></element-citation></ref><ref id="REF6"><label>6</label><element-citation publication-type="journal"><article-title>Recurrence rate during 5-year period after suspension of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration</article-title><source>J Clin Med</source><person-group>
<name><surname>Chujo</surname><given-names>S</given-names></name>
<name><surname>Matsubara</surname><given-names>H</given-names></name>
<name><surname>Mase</surname><given-names>Y</given-names></name>
<name><surname>Kato</surname><given-names>K</given-names></name>
<name><surname>Kondo</surname><given-names>M</given-names></name>
</person-group><fpage>4317</fpage><volume>13</volume><year>2024</year><pub-id pub-id-type="pmid">39124583</pub-id>
</element-citation></ref><ref id="REF7"><label>7</label><element-citation publication-type="journal"><article-title>Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes</article-title><source>Retina</source><person-group>
<name><surname>Chin</surname><given-names>HS</given-names></name>
<name><surname>Park</surname><given-names>TS</given-names></name>
<name><surname>Moon</surname><given-names>YS</given-names></name>
<name><surname>Oh</surname><given-names>JH</given-names></name>
</person-group><fpage>556</fpage><lpage>560</lpage><volume>25</volume><year>2005</year><pub-id pub-id-type="pmid">16077349</pub-id>
</element-citation></ref><ref id="REF8"><label>8</label><element-citation publication-type="journal"><article-title>Anatomic and pharmacokinetic properties of intravitreal bevacizumab and ranibizumab after vitrectomy and lensectomy</article-title><source>Retina</source><person-group>
<name><surname>Christoforidis</surname><given-names>JB</given-names></name>
<name><surname>Williams</surname><given-names>MM</given-names></name>
<name><surname>Wang</surname><given-names>J</given-names></name>
<etal/>
</person-group><fpage>946</fpage><lpage>952</lpage><volume>33</volume><year>2013</year><pub-id pub-id-type="pmid">23407351</pub-id>
</element-citation></ref><ref id="REF9"><label>9</label><element-citation publication-type="journal"><article-title>Effects of suspension of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration in clinical setting</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><person-group>
<name><surname>Matsubara</surname><given-names>H</given-names></name>
<name><surname>Matsui</surname><given-names>Y</given-names></name>
<name><surname>Miyata</surname><given-names>R</given-names></name>
<etal/>
</person-group><fpage>1867</fpage><lpage>1876</lpage><volume>260</volume><year>2022</year><pub-id pub-id-type="pmid">35094126</pub-id>
</element-citation></ref><ref id="REF10"><label>10</label><element-citation publication-type="journal"><article-title>Vitreous VEGF clearance is increased after vitrectomy</article-title><source>Invest Ophthalmol Vis Sci</source><person-group>
<name><surname>Lee</surname><given-names>SS</given-names></name>
<name><surname>Ghosn</surname><given-names>C</given-names></name>
<name><surname>Yu</surname><given-names>Z</given-names></name>
<etal/>
</person-group><fpage>2135</fpage><lpage>2138</lpage><volume>51</volume><year>2010</year><pub-id pub-id-type="pmid">20019364</pub-id>
</element-citation></ref><ref id="REF11"><label>11</label><element-citation publication-type="journal"><article-title>Predicted biological activity of intravitreal VEGF Trap</article-title><source>Br J Ophthalmol</source><person-group>
<name><surname>Stewart</surname><given-names>MW</given-names></name>
<name><surname>Rosenfeld</surname><given-names>PJ</given-names></name>
</person-group><fpage>667</fpage><lpage>668</lpage><volume>92</volume><year>2008</year><pub-id pub-id-type="pmid">18356264</pub-id>
</element-citation></ref><ref id="REF12"><label>12</label><element-citation publication-type="journal"><article-title>Ranibizumab</article-title><source>Drugs</source><person-group>
<name><surname>Blick</surname><given-names>SK</given-names></name>
<name><surname>Keating</surname><given-names>GM</given-names></name>
<name><surname>Wagstaff</surname><given-names>AJ</given-names></name>
</person-group><fpage>1199</fpage><lpage>1206</lpage><volume>67</volume><year>2007</year><pub-id pub-id-type="pmid">17521219</pub-id>
</element-citation></ref><ref id="REF13"><label>13</label><element-citation publication-type="journal"><article-title>Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration</article-title><source>Ophthalmology</source><person-group>
<name><surname>Nguyen</surname><given-names>QD</given-names></name>
<name><surname>Das</surname><given-names>A</given-names></name>
<name><surname>Do</surname><given-names>DV</given-names></name>
<etal/>
</person-group><fpage>963</fpage><lpage>976</lpage><volume>127</volume><year>2020</year><pub-id pub-id-type="pmid">32107066</pub-id>
</element-citation></ref><ref id="REF14"><label>14</label><element-citation publication-type="journal"><article-title>Faricimab. Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</article-title><source>Retina</source><date-in-citation content-type="access-date">
<month>4</month>
<year>2024</year>
</date-in-citation><person-group>
<name><surname>7] Chin</surname><given-names>HS</given-names></name>
<name><surname>Park</surname><given-names>TS</given-names></name>
<name><surname>Moon</surname><given-names>YS</given-names></name>
<name><surname>Oh</surname><given-names>JH</given-names></name>
</person-group><fpage>556</fpage><lpage>560</lpage><volume>25</volume><year>2023</year><uri xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK578376/">https://www.ncbi.nlm.nih.gov/books/NBK578376/</uri></element-citation></ref><ref id="REF15"><label>15</label><element-citation publication-type="journal"><article-title>Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><person-group>
<name><surname>Kataoka</surname><given-names>K</given-names></name>
<name><surname>Itagaki</surname><given-names>K</given-names></name>
<name><surname>Hashiya</surname><given-names>N</given-names></name>
<etal/>
</person-group><fpage>43</fpage><lpage>51</lpage><volume>262</volume><year>2024</year><pub-id pub-id-type="pmid">37668741</pub-id>
</element-citation></ref><ref id="REF16"><label>16</label><element-citation publication-type="journal"><article-title>Factors associated with success of switching to faricimab for neovascular age-related macular degeneration refractory to intravitreal aflibercept</article-title><source>Life (Basel)</source><person-group>
<name><surname>Machida</surname><given-names>A</given-names></name>
<name><surname>Oishi</surname><given-names>A</given-names></name>
<name><surname>Ikeda</surname><given-names>J</given-names></name>
<etal/>
</person-group><fpage>476</fpage><volume>14</volume><year>2024</year><pub-id pub-id-type="pmid">38672747</pub-id>
</element-citation></ref><ref id="REF17"><label>17</label><element-citation publication-type="journal"><article-title>Reproducibility of retinal and choroidal thickness measurements in enhanced depth imaging and high-penetration optical coherence tomography</article-title><source>Invest Ophthalmol Vis Sci</source><person-group>
<name><surname>Ikuno</surname><given-names>Y</given-names></name>
<name><surname>Maruko</surname><given-names>I</given-names></name>
<name><surname>Yasuno</surname><given-names>Y</given-names></name>
<name><surname>Miura</surname><given-names>M</given-names></name>
<name><surname>Sekiryu</surname><given-names>T</given-names></name>
<name><surname>Nishida</surname><given-names>K</given-names></name>
<name><surname>Iida</surname><given-names>T</given-names></name>
</person-group><fpage>5536</fpage><lpage>5540</lpage><volume>52</volume><year>2011</year><pub-id pub-id-type="pmid">21508114</pub-id>
</element-citation></ref></ref-list></back></article>